Christine Eisfeld

Christine Eisfeld

Auto-generated profile, based on publicly available information

Christine Eisfeld

Cancer Registry of North Rhine Westphalia Bochum Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2025 in International Journal of Cancer
Verified
Journal Article
Open access
LMLennart Möller
Lennart Möller
ASAndras Szentkirályi
Andras Szentkirályi
CEChristine Eisfeld
Christine Eisfeld
IWIna Wellmann
Ina Wellmann
FRFranziska Rees
Franziska Rees
ASAndreas Stang
Andreas Stang
Neuroendocrine neoplasms (NENs) of the colon and rectum are a heterogeneous group of epithelial neoplasms with neuroendocrine differentiation. They include well‐differentiated neuroendocrine tumors (NETs), poorly differentiated neuroendocrine carcinomas (NECs) and mixed neuroendocrine‐non‐neuroendocrine neoplasms (MiNENs). Our aim was to calculate incidence, incidence trends and relative survival for colonic and rectal NETs, NECs, and MiNENs. We analyzed data covering the entire German population recorded between 2009 and 2021, calculating age‐standardized incidence rates, annual percent changes, and the relative 5‐year survival probability for the calendar period 2017–2021. Our comprehensive analyses included 12,602 NEN cases, with 59% located in the rectum. NECs, MiNENs and tumors with colonic location showed higher stages. We observed an increase in the incidence of NETs, particularly in patients aged <55 years, and in the incidence of MiNENs, and a constant incidence of NECs. The relative five‐year survival was high for rectal NETs (95.9%, 95%‐CI 94.6; 97.1) and colonic NETs (81.4%, 95%‐CI 78.3; 84.5) and low for colonic NECs (20.5%, 95%‐CI 17.6; 23.4) and rectal NECs (19.2%, 95%‐CI 15.7; 22.6). The increase in the incidence of NETs might be partly due to colorectal cancer screening, improved diagnostics, and changes in classification of NETs. We attribute the increase in incidence of MiNENs to the recent introduction of this morphological category. Higher stages at diagnosis, a higher proportion of NECs and higher median age at diagnosis may contribute to the less favorable survival probabilities associated with colonic as opposed to rectal location.

28 August 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
JSJudith Schütte
Judith Schütte
JRJulia Reusch
Julia Reusch
CKCyrus Khandanpour
Cyrus Khandanpour
CEChristine Eisfeld
Christine Eisfeld
Structural variants (SV) are changes in the genomic landscape that can alter gene expression levels and thus lead to disease development. The most common and best studied SVs in hematological malignancies are chromosomal translocations. Here, parts of two genes that are normally on different chromosomes come into close proximity due to a failure in DNA repair. As a consequence, fusion proteins which show a different function and/or cellular localization compared to the two original proteins are expressed, sometimes even at different levels. The identification of chromosomal translocations is often used to identify the specific disease a patient is suffering from. In addition, SVs such as deletions, duplications, inversions and single nucleotide polymorphisms (SNPs) can occur in hematopoietic cells and lead to their malignant transformations. Changes in the 3D genome structure have also recently been shown to impact disease development. In this review, we describe a variety of SVs occurring in different subtypes of hematological malignancies. Currently, most therapeutic approaches target fusion proteins which are the cellular product of chromosomal translocations. However, amplifications and SNPs also play a role in disease progression and can be targeted. We present some examples for different types of structural variants and how they are currently treated.

22 May 2020 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
CEChristine Eisfeld
Christine Eisfeld
EEEva Eßeling
Eva Eßeling
RWRamona Wullenkord
Ramona Wullenkord
CKCyrus Khandanpour
Cyrus Khandanpour
JRJulia Reusch
Julia Reusch
MSMatthias Stelljes
Matthias Stelljes
Despite significant progress made in the treatment of patients with multiple myeloma (MM) in the last decade, for patients with early relapse or rapidly progressing high-risk disease, allogeneic hematopoietic stem cell transplantation (SCT) might be an option leading to long-term survival. Here, we retrospectively analyzed the outcomes of 90 MM patients who received allogeneic SCT in our center between 1999 and 2017. We specifically assessed the association of impaired humoral immune reconstitution, referred to as immunoparesis, and post-transplant survival. Sixty-four patients received allogeneic SCT in relapse following 2–7 lines of therapy; 26 patients received upfront tandem autologous-allogeneic SCT. With a median follow-up of 76 months, OS and PFS were 52.6% (95% CI 42.9–64.3) and 36.4% (95% CI 27.6–47.9) at 2 years and 38.6% (95% CI 29.2–51.1) and 25.3% (95% CI 17.5–36.4) at 5 years, respectively. Receiving more than two therapy lines prior to transplantation was an independent risk factor for OS (HR 3.68, 95% CI 2.02–6.70) and PFS (HR 3.69, 95% CI 2.09–6.50). In a landmark analysis at day 200, prolonged immunoparesis was associated with reduced OS (HR 3.22, 95% CI 1.14–9.11). Allogeneic stem cell transplantation offers an additional treatment element that may lead to long-term remission in selected patients with poor prognosis, probably exploiting graft-versus-myeloma effects. Immunoparesis could potentially serve as an indicator for impaired survival following allogeneic transplantation, an observation to be further studied prospectively.

4 February 2025 in Die Onkologie
Verified
Journal Article
Closed access
PDF file
CEChristine Eisfeld
Christine Eisfeld
Frederik PetersFrederik Peters
Frederik Peters
ASAnnemarie Schultz
Annemarie Schultz
ASAndreas Stang
Andreas Stang
HKHiltraud Kajüter
Hiltraud Kajüter
CRCecile Ronckers
Cecile Ronckers